An interventional study of Gonorrhea/chlamydia Point-of-Care Testing in Point of Care STI Testing, sponsored by Icahn School of Medicine at Mount Sinai. Recruiting at 1 site in United States. Open to participants aged 16 Years to 24 Years. Per ClinicalTrials.gov, last updated 2026-05-05.
Sponsored by Icahn School of Medicine at Mount Sinai · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 98 studies in Gonorrhea with a site in United States — 11 open to participants now, 11 under way, none of them phase 3. Gonorrhea · United States.
Among the 98 studies in Gonorrhea with a site in United States, this one is the 4th largest by planned enrollment of the 76 interventional ones that give a count, is one of 4 that started in 2026, is one of 38 with no phase, reaches primary completion later than 2 of the 10 other live ones, and was the 94th registered.
168 studies on the registry are indexed under Gonorrhea; 32 are open to participants now.
Browse Gonorrhea studies →11 of the 98 studies in Gonorrhea with a site in United States are open now. Recruiting first, the newest first:
Emory University · Sites in United States
Women only · Healthy volunteers
Westat · Sites in United States
Ages 13–29 · Women only
Tulane University · Sites in United States
Ages 15–26 · Healthy volunteers
Queen's Medical Center · Sites in United States
Ages 14+ · Women only · Healthy volunteers
Northwestern University · Sites in United States
Ages 16–34 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 18 Gonorrhea studies recruiting now, 11 (61%) set no upper age limit and 6 (33%) stop at 75 or younger; 10 take children under 18; 12 take healthy volunteers.
This study: 16 Years to 24 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
98 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 14 · Phase 3 11 · Phase 4 7
First in 1999; this study’s year is marked. 4 started in 2026.
This study's planned enrollment of 6,460 is above the median of 380 across 126 interventional studies indexed under Gonorrhea.
Median enrollment 341 across the 76 interventional studies, 907 across the 21 observational. Of the 85 that completed or were terminated, 37 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 98 have an industry lead sponsor. The 10 most frequent:
Icahn School of Medicine at Mount Sinai is the lead sponsor of 776 studies on the registry; 175 are open to participants now.
Of its 125 completed or terminated interventional studies of FDA-regulated products, 83 (66%) have results posted.
Icahn School of Medicine at Mount Sinai has 1 study filed under Gonorrhea — fewer than ten, so there is no comparison to draw.
2 of the studies in Gonorrhea with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06844045Icahn School of Medicine at Mount SinaiPoint of Care STI Testing | 2026-12-31 |
| NCT06951438Queen's Medical CenterAssessing Acceptability and Feasibiity of STI Self-swab Testing, to be Offered at the Time of Telemed Medication Abortion Provision | 2027-01-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 98 studies in Gonorrhea with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The proposed research hypothesizes that point-of-care testing (POCT) for sexually transmitted infections (STIs) gonorrhea and chlamydia will be a feasible, acceptable, and appropriate implementation strategy for improving HIV testing and Pre-exposure prophylaxis (PrEP) delivery in youth, by increasing opportunities for clinician-patient counseling, decreasing loss to follow up, and allowing for same-day HIV prevention service provision. This hypothesis will be tested in a pragmatic non-randomized trial comparing clinical (HIV testing and PrEP counseling and prescription) and implementation (feasibility, acceptability, and appropriateness) outcomes between adolescents receiving POCT compared to laboratory-based testing at three clinics within a large pediatric health system.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- Patients age 16-24 years receiving POCT or lab-based GC/CT testing
Exclusion Criteria:
- Patients with known or active PrEP prescriptions.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in the intervention arm have received point-of-care testing for sexually transmitted infections.
Behavioral: Gonorrhea/chlamydia Point-of-Care Testing
Participants in the control arm have received lab-based testing for sexually transmitted infections.
Point-of-care testing for sexually transmitted infections.
Rates of HIV Test Completion
Rates of HIV test completion on the day of gonorrhea/chlamydia testing will be compared between those who receive point-of-care vs. lab-based STI testing.
Time frame: Day 1 - Measured on date of STI testing
Number of participants who received PrEP counseling
PrEP counseling will be measured using visit note data from the date of the STI testing encounter
Time frame: Day 1 - Same day as STI testing encounter
Time to STI treatment
Days between STI test order and delivery of antibiotics for STI treatment, measured using EHR data
Time frame: Time from STI diagnosis to treatment, up to 9 months
Plan to share: Yes — All of the individual participant data collected during the trial, after deidentification.
Supporting information: Study protocol, Informed consent form, Analytic code
Time frame: Specify Other Time Frame After the end of the award period. No end date.
Access criteria: Researchers who provide a methodologically sound proposal. Any purpose. Data will be findable for the research community through the NIHM Data Archive Collection.
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Dec 2026, 10 months after the start.
Of 37 non-industry interventional studies with no phase under Gonorrhea, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 43. This study's planned 10 months is below that.
Counting every sponsor, half of 41 studies reached it within 23 months; a quarter within 11 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Icahn School of Medicine at Mount Sinai →